BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

Shares of NASDAQ:BIOL opened at $0.15 on Friday. The company’s 50-day moving average is $0.15 and its 200 day moving average is $0.77. The company has a debt-to-equity ratio of 34.06, a quick ratio of 0.68 and a current ratio of 1.26. The company has a market capitalization of $4.83 million, a P/E ratio of 0.00 and a beta of 0.71. BIOLASE has a fifty-two week low of $0.13 and a fifty-two week high of $32.09.

BIOLASE (NASDAQ:BIOL) last issued its quarterly earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share for the quarter. The company had revenue of $13.49 million during the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.